Clinical Trials
27 trialsVismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Alliance for Clinical Trials in Oncology
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
Precision
Shanxi Province Cancer Hospital
CAVALRY
University of Chicago
CAPIcorn
West German Study Group
AMTEC IIT: Phase 2 Multiarm Study in TNBC
OHSU Knight Cancer Institute
SAFE-CAP
Yale University
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
M.D. Anderson Cancer Center
CaptAin
Imperial College London
HEM-iSMART E
Princess Maxima Center for Pediatric Oncology
ProBio
Karolinska Institutet
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
GBG Forschungs GmbH
PAKT
Queen Mary University of London
SAFIR02_Breast
UNICANCER
ComPAKT
Royal Marsden NHS Foundation Trust
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
National Taiwan University Hospital
SAFIR02_Lung
UNICANCER
AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations
Memorial Sloan Kettering Cancer Center
OLAPCO
Yale University
ProCAID
University Hospital Southampton NHS Foundation Trust
Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy
Samsung Medical Center
plasmaMATCH
Institute of Cancer Research, United Kingdom
RE-AKT
Institute of Cancer Research, United Kingdom
STAKT
University of Nottingham